Network News

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Victoria Stodden to receive Humboldt Research Award

Victoria Stodden, statistician and associate professor at the Daniel J. Epstein Department of Industrial and Systems Engineering at the University of Southern California, has been selected to receive a prestigious Humboldt Research Award. Granted by the Alexander von Humboldt Foundation, the award is bestowed on internationally leading researchers in recognition of outstanding academic achievements. A […]

Speaking the language of DNA

EMBL’s scientists have been instrumental in helping the world understand, decode, archive, and manipulate genomes at scale and across many branches of the evolutionary tree By Ewan Birney, Eileen Furlong, and Arnaud Krebs In 1978, British biochemist Frederick Sanger’s team released the genome sequence of ϕX174 – a virus that infects bacteria. The sequence – the […]

New research group leader at the Max Planck Institute for Medical Research

From January 1, 2025, Roman Sarott and his research group “Chemically Induced Proximity” will develop small molecules with special function: they are designed to induce new interactions between proteins in order to reprogram cellular signaling pathways and thereby open up new therapeutic possibilities. “I am very much looking forward to my new role at the […]

Shanghai Ranking of Academic Subjects: Outstanding Placings for Universität Heidelberg

Clinical medicine internationally in 17th position – medical technology ranks 16th worldwide With medical technology and clinical medicine, Heidelberg University is among the best representatives of the medical sciences worldwide. In the 2024 Global Ranking of Academic Subjects, medical technology ranks 16th internationally, which means second place in Germany. Clinical medicine moves up one place […]

EMBL Agri-Tech Partnership to deliver safe food and environmental health

The partnership will address global food security challenges through optimised agricultural research and data-driven innovation ByEffie Mutasa-Gottgens, Matt Hall, Birgit Kerber, Sarah Dayer, Emily Pomeroy, and Laurène Ramos Martins Feeding a growing global population while adapting to challenges posed by climate change remains one of humanity’s most pressing concerns. Worldwide, crops are under threat from […]

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients MANNHEIM, Germany, Dec. 05, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients […]

Joint research on the next generation of sun screens

The German Cancer Research Center (DKFZ) and Beiersdorf are cooperating on the development of innovative sun protection products – and are working together to educate people about effective protection against harmful UV radiation. Experts predict that climate change and the associated increase in the number of hours of sunshine will lead to a further increase […]

VERAXA Biotech and Navigo Proteins Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin Radio Conjugates

The agreement brings together Navigo Protein’s Affilin® platform with VERAXA’s proprietary click chemistry platform and conjugation expertise HEIDELBERG, and HALLE, Germany, December 12, 2024 — VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, and Navigo Proteins GmbH, an innovator developing next-generation targeted radiotheranostics, announced today the initiation of a research collaboration to evaluate […]